Detail Infos IMMUWIN: Durvalumab (MEDI4736) and Tremelimumab in combination with either Y-90 SIRT or TACE
Universitätsklinikum FreiburgID: 674
EntitätHCC
Therapie-Linie
ED
Altersgruppe
≥18
Phase
II
Ein- / Auschlusskriterien
- Multinodular or large, solitary HCC, not eligible for resection or local ablation, histiologically confirmed
- At least one measurable site of disease as defined by RECIST 1.1 criteria with spiral CT scan or MRI
- No prior systemic anti-cancer therapy
Arzt
Dr. Michael Schultheiß: (michael.schultheiss@uniklinik-freiburg.de)
Study Nurse
Katrin Fütterer: 0761- 27032621; (katrin.fuetterer@uniklinik-freiburg.de), Marina Linder: 0761-27032610; (marina.linder@uniklinik.-freiburg.de), Petra Wessoleck: 0761-27032615; (petra.wessoleck@uniklinik-freiburg.de)